Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous umbilical cord blood mononuclear cell infusion for children with cerebral palsy or cerebral brain injury in Kochi
jRCTb060190039Completed
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous umbilical cord blood-derived mononuclear cells and prednisolone in cerebral palsy (CP), hypoxic-ischemic encephalopathy (HIE) and periventricular leukomalacia (PVL). Primary endpoint: Safety over 36 months. Started Mar 2017; status: completed.
02
Drugs
autologous umbilical cord blood-derived mononuclear cellsprednisolone
03
Conditions
cerebral palsy (CP)hypoxic-ischemic encephalopathy (HIE)periventricular leukomalacia (PVL)
Beyond the preview
Go deeper on jRCTb060190039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTb060190039.